SEARCH

SEARCH BY CITATION

References

  • 1
    Bassetti M, Righi E, Tumbarello M, Di Biagio A, Rosso R, Viscoli C. Candida infections in the intensive care unit: epidemiology, risk factors and therapeutic strategies. Expert Rev Anti Infect Ther 2006; 4: 87585.
  • 2
    Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 30917.
  • 3
    Gudlaugsson O, Gillespie S, Lee K et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 9: 37.
  • 4
    Morgan J, Meltzer MI, Plikaytis BD et al. Excess mortality, hospital stay, and cost due to candidemia: a case–control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005; 26: 5407.
  • 5
    Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005; 41: 12329.
  • 6
    Parkins MD, Sabuda DM, Elsayed S, Laupland KB. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother 2007; 60: 6138.
  • 7
    Garey KW, Rege M, Pai MP et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43: 2531.
  • 8
    Bassetti M, Trecarichi EM, Righi E et al. Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. Diagn Microbiol Infect Dis 2007; 58: 32531.
  • 9
    Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 36405.
  • 10
    Meyer E, Schwab F, Gastmeier P, Ruden H, Heininger A. Antifungal use in intensive care units. J Antimicrob Chemother 2007; 60: 61924.
  • 11
    Cappelletty D, Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy 2007; 27: 36988.
  • 12
    Kim R, Khachikian D, Reboli AC. A comparative evaluation of properties and clinical efficacy of the echinocandins. Expert Opin Pharmacother 2007; 8: 147992.
  • 13
    Zambias RA, Hammond ML, Heck JV et al. Preparation and structure-activity relationships of simplified analogues of the antifungal agent cilofungin: a total synthesis approach. J Med Chem 1992; 35: 284355.
  • 14
    Debono M, Gordee RS. Antibiotics that inhibit fungal cell wall development. Annu Rev Microbiol 1994; 48: 47197.
  • 15
    Nishiyama Y, Uchida K, Yamaguchi H. Morphological changes of Candida albicans induced by micafungin (FK463), a water-soluble echinocandin-like lipopeptide. J Electron Microsc (Tokyo) 2002; 51: 24755.
  • 16
    Wheeler RT, Fink GR. A drug-sensitive genetic network masks fungi from the immune system. PLoS Pathog 2006; 2: e35.
  • 17
    Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 2003; 20: 12136.
  • 18
    Morrison VA. Echinocandin antifungals: review and update. Expert Rev Anti Infect Ther 2006; 4: 32542.
  • 19
    Pfaller MA, Messer SA, Boyken L et al. Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates. J Clin Microbiol 2004; 42: 31179.
  • 20
    Ostrosky-Zeichner L, Rex JH, Pappas PG et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003; 47: 314954.
  • 21
    Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol 2005; 43: 54257.
  • 22
    Pfaller MA, Diekema DJ, Messer SA, Hollis RJ, Jones RN. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob Agents Chemother 2003; 47: 106871.
  • 23
    Cuenca-Estrella M, Rodriguez D, Almirante B et al. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002–2003. J Antimicrob Chemother 2005; 55: 1949.
  • 24
    Messer SA, Diekema DJ, Boyken L, Tendolkar S, Hollis RJ, Pfaller MA. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J Clin Microbiol 2006; 44: 3246.
  • 25
    Messer SA, Kirby JT, Sader HS, Fritsche TR, Jones RN. Initial results from a longitudinal international surveillance programme for anidulafungin (2003). J Antimicrob Chemother 2004; 54: 10516.
  • 26
    Nett J, Andes D. Candida albicans biofilm development, modeling a host-pathogen interaction. Curr Opin Microbiol 2006; 9: 3405.
  • 27
    Tchekmedyian NS, Newman K, Moody MR et al. Special studies of the Hickman catheter of a patient with recurrent bacteremia and candidemia. Am J Med Sci 1986; 291: 41924.
  • 28
    Shin JH, Kee SJ, Shin MG et al. Biofilm production by isolates of Candida species recovered from nonneutropenic patients: comparison of bloodstream isolates with isolates from other sources. J Clin Microbiol 2002; 40: 12448.
  • 29
    Rodriguez D, Park BJ, Almirante B et al. Impact of early central venous catheter removal on outcome in patients with candidaemia. Clin Microbiol Infect 2007; 13: 78893.
  • 30
    Mukherjee PK, Chandra J, Kuhn DM, Ghannoum MA. Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect Immun 2003; 71: 433340.
  • 31
    Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002; 46: 177380.
  • 32
    Ghannoum MA. Are there antifungals that are effective against biofilms?; Oral presentation; symposium 3. The 16th Congress of the International Society for Human and Animal Mycology, Paris, 25–29 June 2006.
  • 33
    Choi HW, Shin JH, Jung SI et al. Species-specific differences in the susceptibilities of biofilms formed by Candida bloodstream isolates to echinocandin antifungals. Antimicrob Agents Chemother 2007; 51: 15203.
  • 34
    Balashov SV, Park S, Perlin DS. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother 2006; 50: 205863.
  • 35
    Cota J, Carden M, Graybill JR, Najvar LK, Burgess DS, Wiederhold NP. In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility. Antimicrob Agents Chemother 2006; 50: 39268.
  • 36
    Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis 2006; 42: 93844.
  • 37
    Kahn JN, Garcia-Effron G, Hsu MJ, Park S, Marr KA, Perlin DS. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob Agents Chemother 2007; 51: 18768.
  • 38
    Cheung C, Guo Y, Gialanella P, Feldmesser M. Development of candidemia on caspofungin therapy: a case report. Infection 2006; 34: 3458.
  • 39
    Osherov N, May GS, Albert ND, Kontoyiannis DP. Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccharomyces cerevisiae. Antimicrob Agents Chemother 2002; 46: 24629.
  • 40
    Wierman M, Obeid K, Baxa D et al. Emergence of Candida glabrata isolates with reduced susceptibility to caspofungin and micafungin, but not anidulafungin. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17–20 2007: Abstract M-512.
  • 41
    Ali A, Vasquez G, Vager D, Vazquez JA. Pharmacodynamics of echinocandins against Candida spp, including strains with reduced susceptibility to micafungin and caspofungin while retaining anidulafungin activity. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17–20 2007: Abstract M-538.
  • 42
    Stevens DA, Espiritu M, Parmar R. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother 2004; 48: 340711.
  • 43
    Chamilos G, Lewis RE, Albert N, Kontoyiannis DP. Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences. Antimicrob Agents Chemother 2007; 51: 22579.
  • 44
    Melo AS, Colombo AL, Arthington-Skaggs BA. Paradoxical growth effect of caspofungin observed on biofilms and planktonic cells of five different Candida species. Antimicrob Agents Chemother 2007; 51: 30818.
  • 45
    Stevens DA, Ichinomiya M, Koshi Y, Horiuchi H. Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin. Antimicrob Agents Chemother 2006; 50: 31601.
  • 46
    Clemons KV, Espiritu M, Parmar R, Stevens DA. Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob Agents Chemother 2006; 50: 12937.
  • 47
    Pfizer. Ecalta® Fachinformation. Karlsruhe: Pfizer, 2007.
  • 48
    MSD. Cancidas® Fachinformation. Haar: MSD, 2006.
  • 49
    Nguyen TH, Hoppe-Tichy T, Geiss HK et al. Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. J Antimicrob Chemother 2007; 60: 1006.
  • 50
    Mistry GC, Migoya E, Deutsch PJ et al. Single- and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations. J Clin Pharmacol 2007; 47: 95161.
  • 51
    Mochizuki N, Matsumoto K, Ohno K et al. Effects of hepatic CYP3A4 activity on disposition of micafungin in liver transplant recipients with markedly small-for-size grafts. Transplant Proc 2006; 38: 364950.
  • 52
    Dowell JA, Stogniew M, Krause D, Damle B. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J Clin Pharmacol 2007; 47: 46170.
  • 53
    Garey KW, Pai MP, Suda KJ et al. Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines. Pharmacoepidemiol Drug Saf 2007; 16: 91927.
  • 54
    Stone JA, Holland SD, Wickersham PJ et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002; 46: 73945.
  • 55
    Stogniew M, Pu F, Henkel T, Dowell J. Anidulafungin biotransformation in humans is by degradation not metabolism. 13th European Congress of Clinical Microbiology and Infectious Diseases, Glasgow, 10–13 May 2003: 1223.
  • 56
    Astellas Pharma. Mycamine® (Micafungin) Prescribing Information. Deerfield, IL: Astellas Pharma, 2008.
  • 57
    Hirata K, Aoyama T, Matsumoto Y et al. Pharmacokinetics of antifungal agent micafungin in critically ill patients receiving continuous hemodialysis filtration. Yakugaku Zasshi 2007; 1127: 897901.
  • 58
    Gubbins PO, Amsden JR. Drug–drug interactions of antifungal agents and implications for patient care. Expert Opin Pharmacother 2005; 6: 223143.
  • 59
    Taber SS, Mueller BA. Drug-associated renal dysfunction. Crit Care Clin 2006; 22: 35774.
  • 60
    Amphotericin B. Fachinformation. München: Bristol-Myers Squibb, 2007.
  • 61
    Dowell JA, Stogniew M, Krause D, Henkel T, Weston IE. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J Clin Pharmacol 2005; 45: 22733.
  • 62
    Colburn DE, Giles FJ, Oladovich D, Smith JA. In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology 2004; 9: 21721.
  • 63
    Hebert MF, Townsend RW, Austin S et al. Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005; 45: 95460.
  • 64
    Joseph JM, Jain R, Danziger LH. Micafungin: a new echinocandin antifungal. Pharmacotherapy 2007; 27: 5367.
  • 65
    Vazquez JA. The safety of anidulafungin. Expert Opin Drug Saf 2006; 5: 7518.
  • 66
    Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 20209.
  • 67
    Kuse ER, Chetchotisakd P, Da Cunha CA et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369: 151927.
  • 68
    Pappas PG, Rotstein CMF, Betts RF et al. Micafungin versus caspofungin for the treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45: 88393.
  • 69
    Reboli AC, Rotstein C, Pappas PG et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 247282.
  • 70
    Rex JH, Bennett JE, Sugar AM et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994; 331: 132530.
  • 71
    Gilead Sciences. Ambisome® (Liposomales Amphotericin B) Fachinformation. Martinsried/München: Gilead Sciences, 2006.
  • 72
    Cornely OA, Lasso M, Betts R et al. Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrobiol Chemother 2007; 60: 3639.
  • 73
    Walsh TJ. Echinocandins – an advance in the primary treatment of invasive candidiasis. N Engl J Med 2002; 347: 20702.
  • 74
    Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 13363.
  • 75
    Zepelin MB, Kunz L, Rüchel R, Reichard U, Weig M, Gross U. Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005. J Antimicrob Chemother 2007; 60: 4248.
  • 76
    Sobel JD, Revankar SG. Echinocandins – first-choice or first-line therapy for invasive candidiasis? N Engl J Med 2007; 356: 24256.
  • 77
    Pappas PG. Treatment guidelines for candidiasis. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17–20 2007: Presentation 159/14.
  • 78
    Pappas PG, Rex JH, Sobel JD et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 16189.
  • 79
    Kullberg BJ, Sobel JD, Ruhnke M et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005; 366: 143542.
  • 80
    A Phase III, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of Isavuconazole Versus Caspofungin Followed by Voriconazole in the Treatment of Candidemia and Other Invasive Candida Infections. Available at: http://www.clinicaltrials.gov, identifier NCT00413218 [accessed on 7 October 2008].